Learning outcomes
By the end of this lesson you should be able to: describe the four components of general anaesthesia and the levels of sedation; contrast suxamethonium with the non-depolarising blockers in mechanism, onset, duration and hazards; state the contraindications to suxamethonium and the alternatives; recognise malignant hyperthermia and manage it, including dantrolene dosing; choose between neostigmine and sugammadex for reversal; and describe the indications and complications of regional anaesthesia.
Prerequisites
Lesson 2 (Applied anaesthetic pharmacology) for the neuromuscular blockers and reversal, Lesson 8 (pre-operative evaluation and monitoring) for the monitoring that detects the complications, and cardiac physiology for the conduction effects of hyperkalaemia.
The big idea
The clinical logic of muscle relaxation follows from the components. Paralysis provides intubating conditions and surgical access to rigid cavities; it buys nothing for hypnosis, so a paralysed patient who is awake cannot move or call out, which is why relaxants are never given without a working anaesthetic. The depolarising blocker suxamethonium gives intubating conditions in 45 seconds and wears off in 10 minutes, which no non-depolarising blocker can match; its account of hazards — hyperkalaemia in the denervated patient, raised intracranial and intraocular pressure, and malignant hyperthermia — is equally unique, and the account is what you are examined on. Finally, every block must be reversed, and the reversal agent depends on the blocker: sugammadex encapsulates rocuronium and vecuronium, neostigmine competes at the receptor, and neither reverses suxamethonium.
Technique choices
| Technique | What it is | Indications | Key points |
|---|---|---|---|
| General anaesthesia | Induction, maintenance with a volatile or intravenous agent, airway control, ventilation | Any surgery, surgery where a regional block is impossible, and patient preference | Gives unconsciousness and immobility, with the risks of airway instrumentation and postoperative nausea; requires full monitoring |
| Regional anaesthesia (spinal, epidural, caudal, plexus and peripheral nerve blocks) | Local anaesthetic deposited at the nerve roots or peripheral nerve, alone or combined with general anaesthesia | Lower-limb and lower-abdominal surgery, fractured neck of femur, caesarean section, postoperative analgesia, and patients with respiratory comorbidity | Avoids airway instrumentation and systemic opioid effects; requires anticoagulant assessment, and is contraindicated at the site of infection or with raised intracranial pressure |
| Monitored anaesthesia care (sedation) | Sedation with retained responsiveness, alone or with a local block | Cataract surgery, endoscopy, minor procedures, and the patient in whom general anaesthesia is undesirable | The patient must remain able to maintain their own airway and respond to commands; deep sedation is general anaesthesia with half the monitoring, so the monitor set is the same |
| Combined techniques | General plus a regional block, or a combined spinal-epidural | Major abdominal, thoracic and orthopaedic surgery, and labour pain relief | Regional blocks reduce opioid use and nausea, speed mobilisation and physiotherapy, and improve pain scores |
| Awake fibre-optic intubation | Intubation performed with the patient breathing spontaneously after topicalisation | Predicted difficult intubation or mask ventilation where induction would compromise the airway | The gold standard for predicted difficulty; requires an experienced operator, topical anaesthesia, an antisialagogue, and a clear plan for failure |
Suxamethonium
| Property | Detail |
|---|---|
| Dose and timing | 1–1.5 mg/kg intravenously (onset 30–60 seconds) or 3–4 mg/kg intramuscularly; duration 5–10 minutes, ended by hydrolysis by plasma cholinesterase |
| Indications | Rapid-sequence induction where a fast onset and a short duration are needed: a full stomach, a potential difficult airway in which early return of muscle tone is desirable |
| Fasciculations and myalgia | Visible fasciculations precede paralysis; postoperative myalgia is common 24–72 hours later, reduced by a small pre-treatment dose of a non-depolarising blocker, an NSAID, or a non-depolarising technique |
| Potassium rise | Serum potassium rises by about 0.5 mmol/L normally — harmless in a normal patient but lethal in one with pre-existing hyperkalaemia or an up-regulated receptor population |
| Intracranial and intraocular pressure | Transiently raised (a transient rise in venous pressure and cerebral blood flow); avoid in penetrating eye injury and in raised intracranial pressure |
| Bradyarrhythmia | Stimulation of cardiac muscarinic receptors (the acetylcholine-like structure of suxamethonium), particularly with a second dose, in children, and in patients on beta-blockers |
| Phase II block | Repeated or large doses produce a block that resembles a non-depolarising block — fade with train of four, reversal with neostigmine |
| Prolonged action (sux apnoea) | Plasma cholinesterase deficiency (inherited or acquired: liver disease, pregnancy, malignancy, echothiophate, glycopyrrolate) prolongs the block; the dibucaine number distinguishes normal from atypical enzyme. Management: sedation, ventilation and wait — not an anticholinesterase |
| Contraindications | Hyperkalaemia of any cause (renal failure, burns after 24 hours to about 60 days, spinal cord injury, stroke with paresis, immobility, muscular dystrophy), malignant hyperthermia susceptibility, hypersensitivity, and a personal or family history of prolonged apnoea |
| Anaphylaxis | Anaphylaxis to suxamethonium and to rocuronium is the commonest cause of intraoperative anaphylaxis; suxamethonium accounts for a substantial share of cases even without previous exposure, so treat with adrenaline, fluids, and referral for follow-up |
NoteWhy does a denervated muscle develop extra receptors? When a neuromuscular junction is silent — after denervation, immobilisation, burns or prolonged disease — acetylcholine receptors proliferate and spread over the whole muscle membrane (up-regulation), so a depolarising agonist suddenly occupies a vastly larger population of receptors and releases a flood of potassium. That single mechanism explains every one of the suxamethonium contraindications on the list.
Non-depolarising blockers
| Agent | Dose and kinetics | Clinical features |
|---|---|---|
| Rocuronium | 0.6 mg/kg: onset 60–90 s, 30–60 min; 1.2 mg/kg: onset 45–60 s | The fastest non-depolarising blocker; the alternative to suxamethonium for a rapid-sequence induction, reversible at any depth by sugammadex; mild vagolytic tachycardia at higher doses |
| Vecuronium | 0.1 mg/kg: onset 60–90 s, 30–60 min | Long-acting and cardiovascularly stable, but long; a common source of residual paralysis when used with short procedures |
| Atracurium | 0.5 mg/kg: onset 2–3 min, 25–40 min | Degrades by Hofmann elimination, so suits renal and hepatic failure; histamine release causes hypotension, flushing and bronchospasm at high speed |
| Cisatracurium | 0.15 mg/kg: onset 2–3 min, 25–45 min | An atracurium isomer with less histamine release and greater potency; the standard intensive-care blocker because of organ-independent elimination |
| Pancuronium | 0.05–0.1 mg/kg: 2–3 min onset, very long | Vagolytic tachycardia; rarely used now but still a cause of residual block when a long-acting drug is used for a short operation |
Watch outResidual paralysis is preventable, and preventing it requires measuring. Common contributors are a long-acting drug for a brief operation, hypomagnesaemia (magnesium antagonises acetylcholine release and potentiates the block), acidosis, hypothermia, volatile agents, aminoglycosides and other antibiotics, calcium-channel antagonists, and failure to use reversal with a check of the train-of-four ratio afterwards. It causes airway obstruction, aspiration, respiratory failure and an increased risk of postoperative pulmonary complications, and is one of the commonest avoidable anaesthetic complications.
Malignant hyperthermia
| Stage | Signs | Interpretation |
|---|---|---|
| Earliest | An unexplained rise in end-tidal carbon dioxide (the only universally reliable early sign), with tachycardia and a rising minute ventilation requirement | Hypermetabolism and carbon dioxide production rise before temperature does, so capnography is the detection tool |
| Muscle | Masseter spasm after suxamethonium (a warning in the child), generalised rigidity, and hyperthermia (rate of rise up to 1 °C every 5 minutes) | Rigidity and fever are late; hyperthermia alone is a late sign and should never be awaited |
| Metabolic | Metabolic acidosis, hyperkalaemia, raised creatine kinase, hyperphosphataemia, myoglobinuria (dark urine), and disseminated intravascular coagulation | Muscle breakdown and cell death, and the point at which renal failure becomes a threat |
| Late | Arrhythmia, cardiac arrest, and (rarely) compartment syndrome from muscle necrosis | Untreated mortality is over 80%; with treatment it is under 5% |
| Step | Action | Detail |
|---|---|---|
| 1 | Stop the trigger and get help | Stop the volatile and suxamethonium, increase oxygen to 100% at 10 L/min or more, hyperventilate to wash out the agent, call the MH hotline and the senior anaesthetist, and abort surgery if it can be done quickly |
| 2 | Give dantrolene | 2.5 mg/kg intravenously, repeated every 5 minutes to a maximum of 10 mg/kg; it binds the ryanodine receptor and blocks calcium release. Reconstitute each vial in 60 mL of sterile water, use multiple people and warmed water, and continue until the heart rate, end-tidal carbon dioxide and temperature fall |
| 3 | Cool | Cold intravenous crystalloid (not Hartmann's if the lactate is being monitored), ice packs to the axillae, neck and groin, gastric, peritoneal and bladder lavage, a forced-air cooler in reverse, and stop at 38 °C to avoid hypothermia |
| 4 | Treat hyperkalaemia and acidosis | Calcium gluconate or chloride for myocardial stabilisation, insulin with dextrose, sodium bicarbonate for the acidosis, and ventricular arrhythmia managed with a beta-blocker-free protocol; avoid calcium-channel blockers |
| 5 | Protect the kidneys and monitor | Maintain a urine output above 1 mL/kg/h with fluid and furosemide or mannitol, monitor creatine kinase, potassium, glucose, coagulation, temperature and arterial gases, and transfer to intensive care. Watch for recrudescence in the first 24–72 hours |
NoteSusceptibility is confirmed by an in-vitro contracture test on muscle biopsy or by genetic testing, and the family needs counselling. Dantrolene is available in the UK hospitals that use volatile agents and suxamethonium, and the recovery of the susceptible patient is uneventful once the trigger has been removed and the patient cooled — a remove-trigger-and-wait strategy is the fallback where dantrolene is delayed, but dantrolene is the only specific treatment. Family members and the patient should be told, and the diagnosis recorded prominently in the notes and on a Medic Alert device.
Reversal
| Agent | For which blockers | Dose and endpoint | Drawbacks |
|---|---|---|---|
| Neostigmine | Non-depolarising only (rocuronium, vecuronium, atracurium) | 0.05 mg/kg (maximum 5 mg) with glycopyrrolate 0.01 mg/kg or atropine 0.02 mg/kg, titrated to a train-of-four ratio above 0.9 | Increases salivation, bronchial secretions, gut motility, bradycardia and the risk of bronchospasm; has a maximum effect, so a deeply blocked patient is not fully reversed; risk of residual paralysis if the block has not recovered enough |
| Sugammadex | Rocuronium and vecuronium only | 2 mg/kg with two twitches; 4 mg/kg for post-tetanic count of 1–2; 16 mg/kg for immediate reversal 3 minutes after 1.2 mg/kg rocuronium | Rapid reversal without muscarinic side effects; cannot reverse suxamethonium or non-steroidal agents; reduces the efficacy of hormonal contraception for a week; rare recurrent paralysis from under-dosing |
| Dantrolene | Malignant hyperthermia | 2.5 mg/kg every 5 minutes to 10 mg/kg total | The specific treatment for malignant hyperthermia; it is not a neuromuscular reversal and its own toxicity is muscle weakness prolonged when combined with calcium-channel blockers |
A 20-year-old with a partial thickness flame burn sustained 48 hours ago requires surgery. Which paralytic, and why?
Worked example: masseter spasm
A 6-year-old boy receives sevoflurane and suxamethonium for insertion of a grommet, and his mouth cannot be opened because the jaw is in spasm. The end-tidal carbon dioxide has risen from 4.8 to 6.2 kPa without any change in the ventilation, and the heart rate has gone from 100 to 130. This is malignant hyperthermia until proven otherwise, and the correct response is immediate: stop the volatile, switch to 100% oxygen at maximum flow and hyperventilate, call for senior and MH team help, give dantrolene 2.5 mg/kg, cool the child actively, check potassium and arterial gases, and continue monitoring in intensive care. Waiting for a temperature rise to confirm the diagnosis, or for the potassium to be reported, is the classic fatal delay — masseter spasm in a child with a rising end-tidal carbon dioxide is a positive sign, not a nuisance.
Common mistakes
Watch outGiving suxamethonium in the burn, spinal cord injury, stroke with paresis, immobile or muscular-dystrophy patient on the principle that 'it's only sux'. The potassium release is lethal, and rocuronium with sugammadex reversal is the standard alternative.
Watch outAwaiting hyperthermia in malignant hyperthermia. Temperature is a late and often absent sign; a rising end-tidal carbon dioxide with unexplained tachycardia, rigidity or masseter spasm, in a patient on a volatile or suxamethonium, is the diagnostic trigger.
Watch outReversing a deep block with neostigmine and extubating. Neostigmine reaches a ceiling effect; with two or fewer twitches, or a train-of-four ratio below 0.3, the block cannot be adequately reversed and the patient must be woken with ventilation support or reversed with sugammadex.
Watch outGiving a muscle relaxant without ensuring hypnosis. A paralysed, awake patient cannot move, breathe out, or tell anyone, so the relaxant is given only after a working sedative-hypnotic and analgesic, and the monitor is set up so the end-tidal agent and the neuromuscular train of four are visible.
Check your understanding
Explain the mechanism by which burns, spinal cord injury and stroke with paresis make suxamethonium dangerous, and the mechanism by which suxamethonium causes a 'phase II block'.
Give the dantrolene dose and the cooling targets in a malignant hyperthermia crisis.
A patient received neostigmine and glycopyrrolate for reversal 20 minutes ago and now has a train-of-four ratio of 0.6 with poor respiratory effort. What is wrong and what is the fix?
Multiple choice
Which is a contraindication to suxamethonium?
Which is the earliest reliable sign of malignant hyperthermia?
What is the correct initial dose of dantrolene in malignant hyperthermia?
Which statement about reversal of neuromuscular blockade is correct?
Summary and next
Anaesthesia has four components — hypnosis, analgesia, amnesia and muscle relaxation — each titrated to its own endpoint. Suxamethonium is fast and short but carries the hyperkalaemia contraindications (burns, spinal cord injury, stroke with paresis, immobility), the risk of raised intracranial and intraocular pressure and malignant hyperthermia; rocuronium at 1.2 mg/kg substitutes when suxamethonium is contraindicated and is reversible at any depth with sugammadex. Malignant hyperthermia is detected by a rising end-tidal carbon dioxide and treated by stopping the trigger, hyperventilating with 100% oxygen, dantrolene 2.5 mg/kg repeatedly to 10 mg/kg, active cooling and intensive care.
Next and last: local anaesthesia and the core procedural skills. Local anaesthetic maximum doses and the treatment of local anaesthetic systemic toxicity are the practical content that every anaesthetist, every emergency physician and every surgeon needs at the bedside.